Impact of epidermal growth factor single-nucleotide polymorphism on recurrence of hepatocellular carcinoma after hepatectomy in patients with chronic hepatitis C virus infection

Cancer Science

Volumn 105, Issue 6, 2014, Pages 646-650

  Yoshiya, Shohei ^a   Fujimoto, Yukiko ^a   Bekki, Yuki ^a   Konishi, Hideyuki ^a,b   Yamashita, Yo ichi ^a   Ikegami, Toru ^a   Yoshizumi, Tomoharu ^a   Shirabe, Ken ^a   Oda, Yoshinao ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b Gotemba Research Laboratories   (Japan)

Author keywords

Epidermal growth factor; Hepatectomy; Hepatocellular carcinoma; Recurrence; Single nucleotide polymorphism

Indexed keywords

ALANINE AMINOTRANSFERASE; DECARBOXYPROTHROMBIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; SERUM ALBUMIN;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CYTOPLASM; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR VOLUME;

EPIDERMAL GROWTH FACTOR; HEPATECTOMY; HEPATOCELLULAR CARCINOMA; RECURRENCE; SINGLE-NUCLEOTIDE POLYMORPHISM;

AGED; CARCINOMA, HEPATOCELLULAR; EPIDERMAL GROWTH FACTOR; FEMALE; GENE FREQUENCY; GENOTYPE; HEPACIVIRUS; HEPATECTOMY; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 84901847936     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12415     Document Type: Article

References (26)

1. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 2010; 7: 448-58.
2. Kanematsu T, Matsumata T, Shirabe K et al. A comparative study of hepatic resection and transcatheter arterial embolization for the treatment of primary hepatocellular carcinoma. Cancer 1993; 71: 2181-6.
3. Torzilli G, Belghiti J, Kokudo N et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations? An observational study of the HCC East-West study group. Ann Surg 2013; 257: 929-37.
4. Adachi E, Maeda T, Matsumata T et al. Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology 1995; 108: 768-75.
5. Shirabe K, Takenaka K, Taketomi A et al. Postoperative hepatitis status as a significant risk factor for recurrence in cirrhotic patients with small hepatocellular carcinoma. Cancer 1996; 77: 1050-5.
6. Mano Y, Shirabe K, Yamashita Y et al. Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis. Ann Surg 2013; 258: 301-5.
7. Fisher DA, Lakshmanan J. Metabolism and effects of epidermal growth factor and related growth factors in mammals. Endocr Rev 1990; 11: 418-42.
8. Limaye PB, Bowen WC, Orr AV, Luo J, Tseng GC, Michalopoulos GK. Mechanisms of hepatocyte growth factor-mediated and epidermal growth factor-mediated signaling in transdifferentiation of rat hepatocytes to biliary epithelium. Hepatology 2008; 47: 1702-13.
9. Shahbazi M, Pravica V, Nasreen N et al. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 2002; 359: 397-401.
10. Lanuti M, Liu G, Goodwin JM et al. A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome. Clin Cancer Res 2008; 14: 3216-22.
11. Piao Y, Liu Z, Ding Z et al. EGF +61A>G polymorphism and gastrointestinal cancer risk: a HuGE review and meta-analysis. Gene 2013; 519: 26-33.
12. Abu Dayyeh BK, Yang M, Fuchs BC et al. A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology 2011; 141: 141-9.
13. Zhong JH, You XM, Gong WF et al. Epidermal growth factor gene polymorphism and risk of hepatocellular carcinoma: a meta-analysis. PLoS One 2012; 7: e32159.
14. Qi P, Wang H, Chen YM, Sun XJ, Liu Y, Gao CF. No association of EGF 5′UTR variant A61G and hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. Pathology 2009; 41: 555-60.
15. Hong L, Han Y, Zhang H, Zhao Q, Yang J, Ahuja N. High expression of epidermal growth factor receptor might predict poor survival in patients with colon cancer: a meta-analysis. Genet Test Mol Biomarkers 2013; 17: 348-51.
16. Inoue K, Torimura T, Nakamura T et al. Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice. Clin Cancer Res 2012; 18: 3924-33.
17. Schiffer E, Housset C, Cacheux W et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 2005; 41: 307-14.
18. Japan LCSGo. General Rules for the Clinical and Pathological Study of Primary Liver Cancer. Tokyo, Japan: Kanehara, 2003.
19. Sobin LH, Wittekind CH. TNM Classification of Malignant Tumors, 5th edn. New York, NY: Wiley-Liss, 1997.
20. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.
21. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-68.
22. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48: 1312-27.
23. Tanabe KK, Lemoine A, Finkelstein DM et al. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA 2008; 299: 53-60.
24. Ito Y, Takeda T, Sakon M et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer 2001; 84: 1377-83.
25. Okamoto M, Utsunomiya T, Wakiyama S et al. Specific gene-expression profiles of noncancerous liver tissue predict the risk for multicentric occurrence of hepatocellular carcinoma in hepatitis C virus-positive patients. Ann Surg Oncol 2006; 13: 947-54.
26. Hoshida Y, Villanueva A, Kobayashi M et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359: 1995-2004.